ReviewBreast care (Basel, Switzerland)2014
Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?
Review in Breast care (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.
- Impact of 18F-FDG PET, PET/CT, and PET/MRI on Staging and Management as an Initial Staging Modality in Breast Cancer: A Systematic Review and Meta-analysis.Clinical nuclear medicine · 2021Pooled it
- Breast surgery for metastatic breast cancer.The Cochrane database of systematic reviews · 2018Pooled it
- A Nomogram and Risk Classification System Predicting the Prognosis of Patients with De Novo Metastatic Breast Cancer Undergoing Immediate Breast Reconstruction: A Surveillance, Epidemiology, and End Results Population-Based Study.Current oncology (Toronto, Ont.) · 2023Trial
- Factors determining survival in oligometastatic breast cancer in a retrospective cohort study from a low and middle income country.Scientific reports · 2026Article
- Stereotactic ablative radiotherapy-driven immunosuppression is associated with poorer progression-free survival in cancer patients.Cancer immunology, immunotherapy : CII · 2025Article
- Stereotactic body radiotherapy for oligometastatic disease: current evidence and future perspectives.International journal of clinical oncology · 2025Review
- Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study.The oncologist · 2024Article
- Survival outcomes for women with a solitary extracranial metastasis from breast cancer.Breast (Edinburgh, Scotland) · 2024Article
- Update Breast Cancer 2023 Part 3 - Expert Opinions of Early Stage Breast Cancer Therapies.Geburtshilfe und Frauenheilkunde · 2023Article
- Management of Oligometastatic Breast Cancer: An Expert Committee's Opinion.Current oncology (Toronto, Ont.) · 2023Article
- Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure.Therapeutic advances in medical oncology · 2023Review
- Breast cancer recurrence: factors impacting occurrence and survival.Irish journal of medical science · 2022Article
- Review
- Imaging of Oligometastatic Disease.Cancers · 2022Review
- Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes.Scientific reports · 2021Article
- Diagnosis, biology and epidemiology of oligometastatic breast cancer.Breast (Edinburgh, Scotland) · 2021Review
- Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization.Cancer medicine · 2021Article
- Role of locoregional surgery in patients with de novo stage IV breast cancer: analysis of real-world data from China.Scientific reports · 2020Article
- Diagnosis of oligometastasis.Translational cancer research · 2020Review
- The role of surgical intervention for isolated breast cancer liver metastasis: Results of case-control study with comparison to medical treatment.Cancer medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A distinctive subset of metastatic breast cancer is represented by the so called 'oligometastatic' disease, characterized by single/few detectable metastatic lesions. A more aggressive multidisciplinary approach can be considered in this patient population: available data report favorable results of 'radical' local therapy for limited metastatic disease at least in a subset of selected patients. Selection bias and the retrospective nature of data do not allow for generalization of the results: the use of such approaches must be individualized and managed within a multidisciplinary team of dedicated specialists. Improvement in surgical and radiation techniques, development of new tools to deliver local chemotherapy, and new procedures (i.e. cryosurgery, laser and microwave ablation) mandate careful evaluation of such single and combined modalities in controlled clinical trials. A more accurate identification of patients with limited metastases and better definition of treatment endpoints will also allow correct patient selection for locally aggressive therapies. This paper focusses on local treatment of the primary tumor and of the most frequent distant disease sites in the presence of oligometastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.